Etrasimod* is a once-daily, oral, highly selective, sphingosine 1-phosphate (S1P) receptor modulator designed for engagement of S1P receptors 1, 4, and 5.
Etrasimod is being studied to evaluate its safety and potential to treat multiple immune-mediated inflammatory diseases of the gastrointestinal tract, including ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis.
Etrasimod is an investigational drug and is not currently approved for use by any regulatory agency. This information is not intended to promote or recommend etrasimod for any use.
Olorinab* is an oral, peripherally acting, nonopioid analgesic under investigation for the management of visceral pain in irritable bowel syndrome. Olorinab is being evaluated to determine its safety and whether it may have sustained efficacy due to full CB2 agonist, with a low risk of psychoactive effects due to high selectivity for CB2 versus CB1.
Olorinab is an investigational drug and is not currently approved for use by any regulatory agency. This information is not intended to promote or recommend olorinab for any use.